Related Experiment Video
Updated: May 22, 2026
07:57
An Alternative Approach to Study Primary Events in Neurodegeneration Using Ex Vivo Rat Brain Slices
Published on: April 11, 2018
Alzheimer culprits: cellular crossroads and interplay
Sylvie Claeysen1, Maud Cochet, Romain Donneger
1CNRS, UMR-5203, Institut de Génomique Fonctionnelle, F-34000 Montpellier, France. sylvie.claeysen@igf.cnrs.fr
Cellular Signalling
|May 26, 2012
Summary
Alzheimer's disease research focuses on amyloid-β (Aβ) peptide production and clearance imbalances. Understanding these mechanisms is key to developing effective Alzheimer's disease preventions.
Area of Science:
- Neuroscience
- Biochemistry
- Pathology
Background:
- Alzheimer's disease (AD) is a leading cause of dementia globally.
- Key pathological hallmarks include amyloid-β (Aβ) plaques and neurofibrillary tangles.
- The amyloid cascade hypothesis is a prominent theory for AD pathogenesis.
Purpose of the Study:
- To review recent discoveries in Alzheimer's disease research.
- To explore the role of Amyloid Precursor Protein (APP) metabolism in AD.
- To highlight strategies for reducing toxic Aβ peptide formation.
Main Methods:
- Review of scientific literature on Alzheimer's disease.
- Analysis of amyloid-β (Aβ) peptide production and clearance pathways.
- Examination of Amyloid Precursor Protein (APP) metabolism and its implications.
Main Results:
- An imbalance in Aβ peptide production versus clearance is implicated in AD.
- APP metabolism via the amyloidogenic pathway produces toxic Aβ peptides.
- The non-amyloidogenic pathway yields beneficial sAPPα fragments.
Conclusions:
- Targeting Aβ peptide formation is a critical therapeutic strategy for AD.
- Further research into APP processing is essential for AD prevention.
- Understanding these molecular mechanisms offers pathways to combat dementia.
More Related Videos
Related Concept Videos
01:23Alzheimer Disease ll: Pathophysiology
Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...
01:29Alzheimer Disease l: Introduction
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
01:26Alzheimer's Disease: Overview
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
01:22Dementia l: Introduction
Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...
01:22Alzheimer's Disease: Treatment
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
01:30Dementia
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual.
The progression of dementia is generally gradual.